|Description||LY 245769 is a leukotriene E4 (LTE4) inhibitor, and it can inhibit the oxidative degradation of LTE4 and N-acetyl-LTE4 in animal model. LY 245769, as one of the omega-trifluoro analogs of leukotrienes, will provide a new tool for interfering with the inactivation of leukotrienes in the omega-oxidation pathway.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
This active molecular is a selective LTD4 antagonist. CP-85958 may become a clinical candidates for the treatment of asthma in the future.
Cgp-33304 is a dual phospholipase A2 inhibiting agent and leukotriene receptor antagonists. It may prevent hypoxia secondary to leukotriene induced bronchoconst...
Zafirlukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of certain natural substances that cau...
LY 210073, an oxoxanthene derivative, has been found to be a LTB4 receptor antagonist that could probably be effective against inflammation and rheumatic disord...
ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...
ONO-4057 is a leukotriene B4 receptor antagonist originated by Ono Pharmaceutical. ONO-4057 is an Immunologic Factor and Immunosuppressive Agent. Clinical trial...
Cgp-35949 is an LTD4 antagonist which has phospholipase inhibitory activity. It represents a new approach to the treatment of asthma.
LY 245769 is a leukotriene E4 (LTE4) inhibitor, and it can inhibit the oxidative degradation of LTE4 and N-acetyl-LTE4 in animal model. LY 245769, as one of the...
LY-25648 is a leukotriene B4 antagonist.
MK-571 sodium salt hydrate
The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1.
This active molecular is a R-enantiomer of MK-571 which is a selective LTD4 receptor antagonist. Verlukast showed [3H]leukotriene D4 binding in guinea-pig with ...
Ono-RS-347 is an SRS-A antagonist and a new leukotriene antagonists.
ICI-198615 is a novel, potent and selective peptide leukotriene antagonist. It may be useful for the the treatment of allergic diseases.
The sodium salt form of CP-199330 which is a chromen derivative and has been found to be a Leukotriene D4 receptor antagonist that was once studied against asth...
U66858, also known as Bunaprolast, is a hydroquinone inhibitor of leukotriene synthesis, which inhibits LTB4 production in human whole blood.
KP496, a novel dual antagonist of cysLT receptor and TP, is currently in clinical development as a dry powder inhaler. KP496 inhibited epithelial hypertrophy an...
LY 203647 is a a leukotriene D4 and E4 receptor antagonist with a tetrazole nucleus structure originated by Eli Lilly. No development for treatment of Ischaemic...
LY 292728, an oxoxanthene derivative, has been found to be a leukotriene B4 receptor antagonist that has once been studied as an antiasthmatic agent.
This active molecular is a competitive leukotriene B4 receptor antagonist and IC50 value is about 100 nM. LY 255283 is selective for the BLT2 receptor, since IC...
HAMI3379 is a cysteinyl leukotriene 2 (CysLT2) receptor antagonist. It can inhibit radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC5...